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BY-NC-ND license (http://creativeAbstract Increasing prostaglandin E2 by knocking out its inhibitor 15-hydroxyprostaglandin
dehydrogenase (15-PDGH) or administering a compound that inhibits 15-PDGH was recently
found to improve healing in hematopoietic stem cell transplants, colitis recovery, and hepato-
genesis after transection in mice. These results are suggestive of pharmacologic therapies or
even genetic therapy that could improve patient outcomes, especially since the excess
PGE2 and the 15-PDGH inhibitor have proven to be non-toxic. However, elevated levels of
PGE2 are associated with increased risk of cancer and blood clotting problems. It would be un-
acceptable to treat a cancer patient with chemotherapy and replenish the hematopoietic stem
cells with the help of PGE2, only to have increased expression of PGE2 and induce another can-
cer. Therefore, to assess the most therapeutic aspects of PGE2, it is important to consider ef-
fects that could induce disease.
Copyright ª 2015, Chongqing Medical University. Production and hosting by Elsevier B.V. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).Promoting healing by elevated PGE2
Prostaglandin E2 is a lipid signaling molecule that has
diverse functions, ranging from fever mediation to vasodi-
lation, uterine contractions during labor to stimulation of
bone resorption. A recent article from Zhang et al.
discovered that inhibiting 15-hydroxyprostaglandin dehy-
drogenase, an enzyme that physiologically oxidizes PGE2 to
keep it from binding to prostaglandin receptors, leads to
improvements in hematopoietic stem cell transplants, co-
litis recovery, and hepatogenesis after transection in mice.
These results were consistent for both mice with the gene
for 15-PDGH knocked out, as well as those that were
administered with a pharmacologic dose of SW033291, anity of Chongqing Medical
15.09.002
ng Medical University. Production
commons.org/licenses/by-nc-nd/inhibitor of 15-PDGH that was discovered through high
throughput screening.1
After chemical/genetic ablation of 15-PDGH, mice that
received administration of oral dextran sodium sulfate
(DSS) for seven days had a decrease in the number of colon
ulcers, total area of ulcerated colon mucosa, mucosal
inflammation, diarrhea, rectal bleeding, colon shortening,
and inflammatory cytokines. On the other hand, wild type
mice with 15-PDGH knockout bone marrow transplants did
not see such effects. Observations of BrdU incorporation
and presence of cleaved caspase 3 indicated that inhibition
of 15-PDGH prevented DSS-induced colitis through
increased cell proliferation, not by inhibiting apoptosis.1
In addition, inhibiting 15-PDGH can aid in abnormal
wound healing. Hypertrophic scars can form after severe
burns or poor wound healing conditions lead to excessive
proliferation of fibroblasts, producing excessive extracel-
lular matrix. Administration of TD88, a 15-PDGH inhibitor,and hosting by Elsevier B.V. This is an open access article under the
4.0/).
296 Editorialleads to increased Type IV collagen and decreased wound
healing factors (PDGF, CTGF, TIMP-2) at the injury site,
preventing the excessive wound scarring that occurs with
suppression of PGE2.2 Inhibiting 15-PDGH allows for
improved reepithelization on wounded surfaces (Fig. 1).
Potential adverse effects of elevated levels of
PGE2
Promoting tumorigenesis
Though Zhang et al. noted that the 15-PDGH inhibitor was
not toxic, long-term effects of elevated PGE2 could lead to
pathologies such as tumorigenesis or hemostatic perturba-
tions. Lack of short-term toxicity does not indicate safety in
the long term.
PGE2’s signaling through the Wnt pathway, first identi-
fied for its role in carcinogenesis, and its many effects that
align with the hallmarks of cancer (e.g., increased cell
proliferation, angiogenesis, etc.) indicate that complica-
tions due to over-expression of PGE2 must be considered.
Reduced expression of 15-PGDH leads to prolonged
availability and action of PGE2 and has been linked to
several cancers, including colorectal, bladder, pancreatic,
and gastric adenocarcinomas. 15-PDGH knockout mice have
been shown to have a 7.6-fold increase in colon tumors and
confers carcinogen susceptibility to normally resistant
mice, concomitant with a doubling of 15-PGDH. In familial
adenomatous polyposis (FAP), there is a universal loss of 15-
PGDH expression, including adenomas as small as a single
crypt.3 In both human FAP and murine models of the dis-
ease, COX-2 is constitutively over-expressed in the colon.4
In fact, measuring the levels of PGE2 metabolites in
urine, such as 13,14-dihydro-15-keto-PGE2, has been used
to demonstrate the increased synthesis of PGE2 in in-
dividuals with colorectal and lung cancer.5e7 TreatmentFig. 1 PGE2 production and its potential healing effect on tissue
begins with the conversion of a phospholipid from the membran
inhibiting COX enzymes and PGE2 synthesis using NSAIDs, Zhang et a
or delivering an inhibitor (SW03329). (B) Inhibition of PGE2 degradat
colitis models, and bone marrow transplantations although the pot
long-term uses of PGE2 should be considered.with NSAIDs, which inhibits PGE2 synthesis, prevents tumor
formation in mouse models of FAP.4
Other cancers are also closely associated with 15-PDGH
regulation. Given the already proliferative nature of he-
patocytes, further inducing cellular growth could warrant
cancerous growth, as has been indicated by previous
studies.8 Partial hepatectomies of half the liver volume in
humans need about 12 weeks to regain liver function.9
Whether this is enough time for excess PGE2 to induce
neoplasms has yet to be determined.
PGE2 is associated with growth-stimulation in breast
cancer, oftenwith COX-2 overexpressed. Up-regulation of 15-
PDGH decreases clonal growth and cellular ability to form
tumors in vivo, while silencing 15-PDGH enhances cellular
proliferation and tumorigenesis, suggesting that 15-PDGH
could be a novel tumor suppressor gene in breast cancer.10
Lung tumors have shown increased expression COX-2 and a
PGE2 synthesis enzyme, with a reciprocal relationship be-
tween COX-2 and 15-PDGH expression.11 Under-expression of
15-PDGH in lung tumors suggests that 15-PDGH might behave
as a tumor suppressor in lung cancer.12
PGE2 also feeds back to positively increase COX-2 expres-
sion, further augmenting its own synthesis. In the microenvi-
ronment of the tumor, this creates a vicious cycle where
tumor-related signaling increases COX-2 expression leading to
PGE2 production, which not only drives angiogenesis while
suppressing apoptosis and innate immunity but also heightens
COX-2 expression and perpetuates PGE2 synthesis.13
Though the effect of PGE2 is local, as an autocrine and
paracrine lipid mediator, the administration of SW033291 is
systemic, its major effectors being bone marrow, the colon,
and the liver. Knockout mice have a similarly systemic ef-
fect. Since PGE2 feeds back to increase COX2 expression,
which is typically absent from most cell types until in-
flammatory mediators like TNF-a and IL-1b induce its
expression, excess PGE2 from 15-PDGH inhibition could
likely have serious carcinogenic effects.injury. (A) The making and breaking of PGE2. PGE2 synthesis
e bilayer to PLA2. While most PGE2 studies have focused on
l focused on inhibiting 15-PDGH by either knocking out its gene
ion may lead to improved healing for hepatectomies, ulcerative
ential for disease-causing adverse effects of high-dose and/or
Editorial 297Perturbing hemostasis
Inhibition of 15-PDGH would lead to decreased PGE2 degra-
dation, thus disrupting the physiological levels of PGE2. Low
concentrations of PGE2 enhance platelet aggregation,
whereas high PGE2 levels inhibit aggregation.14e18 Among
the four PGE2 receptors (EP1-EP4), activation of EP3 is suf-
ficient to mediate the proaggregatory actions of low PGE2
concentration. In contrast, the prostacyclin receptor (IP)
mediates the inhibitory effect of higher PGE2 concentra-
tions. The relative activation of these two receptors, EP3 and
IP, regulates the response of platelets to aggregating agents.
PGE2 has been shown to facilitate arterial thrombosis by
acting via EP316; loss of the EP3 receptor has been shown to
prevent intravascular clots.15
Stimulation of receptors EP2 and EP4 usually increases
intracellular cAMP levels through activation of Gas protein,
resulting in decrease of intracellular calcium levels. This
results in inhibition of platelet aggregation, calcium mobi-
lization, and upregulation of P-selectin. Furthermore, EP4
activation enhances the inhibitory effect of aspirin,19
acting as a potent inhibitor of platelet function with
respect to adhesion, aggregation, and thrombosis.20 While
it may seem like activation of EP4 could balance out the
pro-aggregatory effects of EP3, the exact effects of
administration of PGE2 on the balance between thrombotic
and anti-thrombotic effects is unknown. It would be pru-
dent to consider blood clotting pathologies like dissemi-
nated intravascular coagulation as possible complications
before moving forward with using 15-PDGH inhibitors as a
therapeutic solution.
Future directions
The results of increased production of PGE2 in mice through
the inhibition of 15-PDGH appear to have many promising
effects for healing, specifically within bone marrow, the
colon, and the liver. It would be interesting to investigate if
such healing promoting effects of PGE2 can be extended to
the injuries of other tissues, such as soft tissues, bone, and
skeletal tissues. Considering the dysregulation that could
potentially result, erring toward the side of cell prolifera-
tion, additional investigation into potentially carcinogenic
or adverse thrombotic events after long-term use is needed
before its merits can be considered as a part of standard
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